XML 54 R23.htm IDEA: XBRL DOCUMENT v2.4.0.8
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
9 Months Ended
Sep. 30, 2013
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule Of Changes In Carrying Amount Of Goodwill
Changes in the carrying amount of goodwill for the nine months ended September 30, 2013 were as follows:
 
 
U.S.
Neurosurgery
 
U.S.
Instruments
 
U.S.
Extremities
 
U.S.
Spine
and
Other
 
International
 
Total
 
(In thousands)
Goodwill, gross
$
94,312

 
$
57,514

 
$
60,353

 
$
56,219

 
$
25,669

 
$
294,067

Accumulated impairment losses


 


 


 


 


 


Goodwill at December 31, 2012
94,312

 
57,514

 
60,353

 
56,219

 
25,669

 
294,067

Tarsus Medical, Inc. acquisition


 


 
180

 


 


 
180

Goodwill impairment charge

 

 

 
(46,738
)
 

 
(46,738
)
Foreign currency translation
494

 
300

 
316

 
70

 
135

 
1,315

Balance at September 30, 2013
$
94,806

 
$
57,814

 
$
60,849

 
$
9,551

 
$
25,804

 
$
248,824

Components Of Company's Identifiable Intangible Assets
The components of the Company’s identifiable intangible assets were as follows:
 
 
Weighted
Average
Life
September 30, 2013
 
Weighted
Average
Life
December 31, 2012
 
Cost
 
Accumulated
Amortization
 
Net
 
Cost
 
Accumulated
Amortization
 
Net
 
(Dollars in thousands)
Completed technology
12 years
$
80,835

 
$
(43,512
)
 
$
37,323

 
12 years
$
75,692

 
$
(38,402
)
 
$
37,290

Customer relationships
12 years
146,914

 
(77,361
)
 
69,553

 
12 years
147,690

 
(70,005
)
 
77,685

Trademarks/brand names
31 years
33,750

 
(15,516
)
 
18,234

 
31 years
33,807

 
(15,034
)
 
18,773

Trademarks/brand names
Indefinite
48,484

 

 
48,484

 
Indefinite
48,484

 

 
48,484

Supplier relationships
27 years
34,721

 
(8,933
)
 
25,788

 
27 years
34,721

 
(7,817
)
 
26,904

All other (1)
4 years
4,830

 
(1,802
)
 
3,028

 
4 years
4,519

 
(1,388
)
 
3,131

 
 
$
349,534

 
$
(147,124
)
 
$
202,410

 
 
$
344,913

 
$
(132,646
)
 
$
212,267

 
(1) 
At September 30, 2013 and December 31, 2012, all other included in-process research and development of $2.1 million and $1.7 million, respectively, which was indefinite-lived.